Dietary Supplement Climea Forte 30tabs.

Product Information

receiving reports on adverse effects (the legal basis for processing is a legal obligation to which Aflofarm is subject – Article 6(1)(c) of the GDPR); Inform postmenopausal women of possible less serious but common adverse reactions of estrogen-alone therapy such as headache, breast pain and tenderness, nausea and vomiting. Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertility

Preparat zawiera wyciągi roślinne iwitaminy. 1tabletka zawiera: 50 mg izoflawonów znasion soi, 30 mg wyciągu zszyszek chmielu, 10 mg wyciągu znasion lnu, 400 mg wapnia, 5µg witaminy D3, 1,4 mg witaminy B6, 12 mg witaminy E, 0,2 mg kwasu foliowego. In the WHI estrogen-alone substudy, the risk of VTE (DVT and PE) was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years 3. Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately. A 2-to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported. HypercalcemiaOther binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-l-antitrypsin, ceruloplasmin). Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity. Start therapy with 0.025 mg per day applied to the skin once weekly. Therapy should be started at the lowest effective dose and the shortest duration consistent with the treatment goals. Attempts to taper or discontinue the medication should be made at 3 to 6 month intervals. Treatment Of Hypoestrogenism Due To Hypogonadism, Castration, Or Primary Ovarian Failure Climea форте ги ублажуваат симптомите на менопауза, ги штитат клетките од слободните радикали, помагаат во одржување на здрави коски, одржување на соодветно ниво на холестерол, помагаат во контрола на телесната тежина и го намалуваат заморот и уморот. Climea forte го прави најтешкиот период во животот на возрасната жена поблаго искуство. Позитивно влијае и на телото на жената и на нејзината психичка состојба. Температурата на телото на жената е изедначена. Се намалува потењето. Вртоглавицата што ја придружува менопаузата исчезнува, особено во нејзиниот прв циклус. Гадење се намалува. Затоа, препаратот се препорачува да го користат жени кои значително ги доживуваат овие заболувања, што им го отежнува нормалното функционирање, работата, комуникацијата со други или вршењето механички активности, како што е возењето. Контраиндикации There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Breast Cancer

The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA. Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, and increased triglyceride levels. The effects are related to the content of soybean and hop cone extracts, which help alleviate menopausal symptoms, such as hot flashes, sweating, anxiety, and irritability. Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med. 2006;166:357-365. If your personal data are processed based on your consent, you may withdraw your consent to personal data processing at any time, whereas this will not affect lawfulness of prior processing.Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since menopause (8 versus 16 per 10,000 women-years). 1 Climara Forte should be applied immediately after opening the pouch and removing the protective liner. The data described below reflect pooled data from 5 clinical trials of Climara Forte. A total of 614 women were exposed to Climara Forte for 3 months (193 women at 0.025 mg per day, 201 women at 0.05 mg per day, 194 women at 0.1 mg per day) in randomized, double-blind trials of clinical efficacy versus placebo and versus active comparator. All women were postmenopausal, had a serum estradiol level of less than 20 pg/mL, and a minimum of five moderate to severe hot flushes per week or a minimum of 15 hot flushes per week of any severity at baseline. Included in this table are an additional 25 postmenopausal hysterectomized women exposed to Climara Forte 0.025 mg per day for 6 to 24 months (N=16 at 24 months) in a randomized, double-blind, placebo-controlled study of Climara Forte for the prevention of osteoporosis. CLIMEA Forte to preparat którego zadaniem jest złagodzenie objawów menopauzy oraz profilaktycznie w osteoporozie. Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary. Treatment Of Moderate To Severe Vasomotor Symptoms Due To Menopause